Compare · CCEL vs FMS
CCEL vs FMS
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Fresenius Medical Care AG (FMS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and FMS operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $19.85B, about 238.2x CCEL ($83.3M).
- Over the past year, CCEL is down 36.5% and FMS is down 9.1% - FMS leads by 27.3 points.
- CCEL has been more active in the news (2 items in the past 4 weeks vs 1 for FMS).
- FMS has more recent analyst coverage (21 ratings vs 0 for CCEL).
- Company
- Cryo-Cell International Inc.
- Fresenius Medical Care AG
- Price
- $3.59-2.18%
- $22.76+0.02%
- Market cap
- $83.3M
- $19.85B
- 1M return
- +16.56%
- +2.18%
- 1Y return
- -36.46%
- -9.14%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 2
- 1
- Recent ratings
- 0
- 21
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest CCEL
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives NYSE American Continued Listing Notice
- SEC Form 10-K filed by Cryo-Cell International Inc.
- Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
- SEC Form 4 filed by Chairman, Co-CEO Portnoy David
- SEC Form 4 filed by Co-CEO Portnoy Mark L.
- SEC Form 4 filed by Chief Information Officer Mikulinsky Oleg
- SEC Form 4 filed by VP Finance, CFO Taymans Jill M
Latest FMS
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 3 filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form IRANNOTICE filed by Fresenius Medical Care AG
- SEC Form 20-F filed by Fresenius Medical Care AG
- Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by Goldman
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned